During the last session, Transmedics Group Inc (NASDAQ:TMDX)’s traded shares were 1.68 million, with the beta value of the company hitting 2.10. At the end of the trading day, the stock’s price was $62.55, reflecting an intraday gain of 0.94% or $0.58. The 52-week high for the TMDX share is $177.37, that puts it down -183.57 from that peak though still a striking 12.07% gain since the share price plummeted to a 52-week low of $55.00. The company’s market capitalization is $2.10B, and the average intraday trading volume over the past 10 days was 3.68 million shares, and the average trade volume was 2.32 million shares over the past three months.
Transmedics Group Inc (TMDX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.70. TMDX has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.15.
Transmedics Group Inc (NASDAQ:TMDX) trade information
Transmedics Group Inc (TMDX) registered a 0.94% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.94% in intraday trading to $62.55, hitting a weekly high. The stock’s 5-day price performance is 3.49%, and it has moved by 3.34% in 30 days. Based on these gigs, the overall price performance for the year is -29.01%. The short interest in Transmedics Group Inc (NASDAQ:TMDX) is 9.15 million shares and it means that shorts have 5.42 day(s) to cover.
The consensus price target of analysts on Wall Street is $109, which implies an increase of 42.61% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $90 and $125 respectively. As a result, TMDX is trading at a discount of -99.84% off the target high and -43.88% off the low.
Transmedics Group Inc (TMDX) estimates and forecasts
Statistics show that Transmedics Group Inc has outperformed its competitors in share price, compared to the industry in which it operates. Transmedics Group Inc (TMDX) shares have gone down -59.74% during the last six months, with a year-to-date growth rate more than the industry average at 229.87% against 14.80. In the rating firms’ projections, revenue will increase 77.76% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 109.49M as predicted by 8 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 119.4M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 81.17M and 96.85M respectively. In this case, analysts expect current quarter sales to grow by 34.88% and then jump by 23.28% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 8.36%. While earnings are projected to return 227.30% in 2025.
TMDX Dividends
Transmedics Group Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Transmedics Group Inc (NASDAQ:TMDX)’s Major holders
Transmedics Group Inc insiders own 3.21% of total outstanding shares while institutional holders control 113.38%, with the float percentage being 117.15%. FMR LLC is the largest shareholder of the company, while 496.0 institutions own stock in it. As of 2024-06-30, the company held over 4.49 million shares (or 13.7063% of all shares), a total value of $676.31 million in shares.
The next largest institutional holding, with 2.65 million shares, is of BLACKROCK INC.’s that is approximately 8.0755% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $398.47 million.
Also, the Mutual Funds coming in first place with the largest holdings of Transmedics Group Inc (TMDX) shares are iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund . Data provided on Oct 31, 2024 indicates that iShares Core S&P Smallcap ETF owns about 2.12 shares. This amounts to just over 6.33 percent of the company’s overall shares, with a $132.92 million market value. The same data shows that the other fund manager holds slightly less at 1.02, or about 3.04% of the stock, which is worth about $63.77 million.
